We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

235 hedge funds and large institutions have $3.22B invested in Array Biopharma Inc in 2018 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 83 increasing their positions, 62 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 20

46% more call options, than puts

Call options by funds: $27.3M | Put options by funds: $18.7M

34% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 62

26% more capital invested

Capital invested by funds: $2.56B → $3.22B (+$660M)

23% more funds holding

Funds holding: 191 → 235 (+44)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

Holders
235
Holders Change
+44
Holders Change %
+23.04%
% of All Funds
5.39%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
66
Increased
83
Reduced
62
Closed
20
Calls
$27.3M
Puts
$18.7M
Net Calls
+$8.62M
Net Calls Change
-$12.9M

Top Buyers

1
FCM
Farallon Capital Management
California
+$49.6M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$39.5M
3
American Century Companies
American Century Companies
Missouri
+$25.4M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$22.8M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
+$19.6M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$84.3M
2
BI
BVF Inc
California
-$58M
3
ACA
Avoro Capital Advisors
New York
-$56.8M
4
O
OrbiMed
New York
-$43.6M
5
Morgan Stanley
Morgan Stanley
New York
-$33.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
176
Piermont Capital Management
Missouri
$361K -$55.6K -3,470 -14%
SAM
177
Shell Asset Management
Netherlands
$355K – – –
Brown Advisory
178
Brown Advisory
Maryland
$354K +$347K +21,692 New
SO
179
STRS Ohio
Ohio
$344K +$304K +19,000 +905%
SGAM
180
Smith Group Asset Management
Texas
$327K +$321K +20,040 New
NSEDCP
181
NJ State Employees Deferred Compensation Plan
New Jersey
$326K -$400K -25,000 -56%
KAM
182
Kazazian Asset Management
Florida
$317K -$159K -9,938 -34%
FMT
183
First Mercantile Trust
Tennessee
$316K +$82.4K +5,146 +36%
II
184
Ibex Investors
Colorado
$307K +$301K +18,784 New
TI
185
Trexquant Investment
Connecticut
$289K -$1.54M -96,116 -84%
Verition Fund Management
186
Verition Fund Management
Connecticut
$286K +$280K +17,505 New
AIP
187
Ameritas Investment Partners
Nebraska
$282K – – –
SG Americas Securities
188
SG Americas Securities
New York
$262K +$257K +16,065 New
SQA
189
Simon Quick Advisors
New Jersey
$260K – – –
Janney Montgomery Scott
190
Janney Montgomery Scott
Pennsylvania
$252K -$132K -8,236 -35%
SEI Investments
191
SEI Investments
Pennsylvania
$245K +$241K +15,037 New
D.E. Shaw & Co
192
D.E. Shaw & Co
New York
$232K -$3.56M -222,218 -94%
GC
193
Grimes & Company
Massachusetts
$228K +$224K +14,000 New
QSS
194
Quantitative Systematic Strategies
Florida
$226K +$9.61K +600 +5%
MAM
195
Martingale Asset Management
Massachusetts
$218K +$213K +13,327 New
HMS
196
Hanseatic Management Services
New Mexico
$216K +$211K +13,164 +18,283%
BCM
197
Bayesian Capital Management
New York
$215K +$211K +13,200 New
Royal Bank of Canada
198
Royal Bank of Canada
Ontario, Canada
$211K +$150K +9,363 +267%
GCP
199
GSA Capital Partners
United Kingdom
$208K +$204K +12,746 New
TAM
200
Tocqueville Asset Management
New York
$204K +$200K +12,500 New
6 7
8
9 10

ARRY Hedge Fund Activity: Q1 2018 in Review

235 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2018, worth a combined $3.22B — up 26% from $2.56B a quarter earlier.

Buyers outnumbered sellers: 66 funds opened new ARRY positions and 20 closed out — a net gain of 46 holders — while 83 added to existing stakes and 62 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $49.6M. The largest seller was Point72 Asset Management, cutting an estimated $84.3M.

  • 235 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2018, up from 191 in Q4 2017.
  • Funds reported $3.22B of Array Biopharma Inc stock for Q1 2018, up 26% quarter-over-quarter.
  • 66 funds opened new Array Biopharma Inc positions in Q1 2018 and 20 closed out, a net change of +46 holders.
  • The largest Array Biopharma Inc buyer in Q1 2018 was Farallon Capital Management, an estimated $49.6M added.
  • The largest Array Biopharma Inc seller in Q1 2018 was Point72 Asset Management, an estimated $84.3M sold.

Based on aggregated 13F filings for Q1 2018.